Cost Effective and Efficient Progression of Lead Drug Candidates to First in Human Studies

Hosted by ISSX, Frontage's own Dr John Kapeghian discusses the "Cost Effective and Efficient Progression of Lead Drug Candidates to First in Human Studies in the Two Largest Economies in the World: USA and China."

"*" indicates required fields

X/Twitter

This field is for validation purposes and should be left unchanged.

First Name*

Last Name*

Company*

State*

Country

Email*

Phone*

Please only hit the submit button once.

I AGREE*

By submitting this form I agree that Frontage may process my data in the manner described in Frontage’s Privacy Policy.

Cost Effective and Efficient Progression of Lead Drug Candidates to First in Human Studies

Resources to Consider

The role of genetic toxicology in drug development

Drug-drug Interaction Study of CYP3A4 Inhibitors with Colchicine Oral...

Human Gut Microbiome-Based Contract Research Applications in...

Bioanalytical Drug Tolerance Limit Prediction and Optimization Model...

Accurate determination of drug-to-antibody ratio of interchain...

Simultaneous quantification of total antibody and antibody-conjugated...

WRIB 2025: Innovative Strategy for Overcoming pH-Related Assay...

WRIB 2025: Integrated Non-cell Based and Cell-based NAb Assays for a...

Drug Metabolism and Pharmacokinetics (DMPK) Services

Quantitative Assessment of mRNA Drug Biological Activity by...

Hepatitis A Virus Infection In Cynomolgus Monkeys Confounds The...

Development of Stable Nanoemulsion Formulation as an Ophthalmic Drug...